/Investor DB

Panacea Venture — 2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

Domain Therapeuticsdomaintherapeutics.comin𝕏May 2022 · $42M

Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.

BiotechDigital Health

Co-investors3B Future Health FundCTI Life Sciences Fund L.P.adMare BioInnovationsOmnes CapitalSeventure Partners

hC Biosciencehcbioscience.comNov 2022Defunct

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

Leslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in

Co-investorsARCH Venture Partners5AM Ventures8VCAtlas VentureTaiho Ventures, LLCTakeda Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.